Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Colorectal Neoplasms 45 Rectal Neoplasms 35 Stomach Neoplasms 27 Pancreatic Neoplasms 27 Neoplasm Metastasis 24 Neoplasms 19 Colonic Neoplasms 18 Triple Negative Breast Neoplasms 7 Esophageal Neoplasms 6 Adenocarcinoma 6 Liver Neoplasms 5 Brain Neoplasms 5 Carcinoma, Renal Cell 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Hepatocellular 4 Ovarian Neoplasms 3 Head and Neck Neoplasms 3 Colorectal Cancer Metastatic 3 Carcinoma, Ovarian Epithelial 3 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms, Unknown Primary 2 Melanoma 2 Gastrointestinal Neoplasms 2 Gallbladder Neoplasms 2 Fallopian Tube Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Squamous Cell 2 Carcinoma 2 Breast Neoplasms, Male 2

Interventions

pasireotide 3 lanreotide 1 Temozolomide 1 Rosiglitazone 1 Pafolacianine 1 Endoscopic Mucosal Resection 1 Dexamethasone 1 Capecitabine 1 Calcium Dobesilate 1 Cabergoline 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Pituitary Neoplasms × Capecitabine × Clear all

NCT03930771 2022-08-09

TMZ-Cap

Weill Medical College of Cornell University

Phase 2 Terminated

1 enrolled 8 charts

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡